Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Clinical trial NCT03223610 · RECRUITING
Trial details
- NCT number
- NCT03223610
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-09
- Primary completion
- 2026-12-01
- Enrollment
- 155
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.